[go: up one dir, main page]

BRPI0516992A - método de potencializar modulação imune e inflamatória para célula e terapia de droga - Google Patents

método de potencializar modulação imune e inflamatória para célula e terapia de droga

Info

Publication number
BRPI0516992A
BRPI0516992A BRPI0516992-5A BRPI0516992A BRPI0516992A BR PI0516992 A BRPI0516992 A BR PI0516992A BR PI0516992 A BRPI0516992 A BR PI0516992A BR PI0516992 A BRPI0516992 A BR PI0516992A
Authority
BR
Brazil
Prior art keywords
cell
drug therapy
inflammatory
ucbcs
optimal time
Prior art date
Application number
BRPI0516992-5A
Other languages
English (en)
Inventor
Alison Willing
Paul R Sanberg
Mary B Newman
Cyndy Davis Sanberg
Original Assignee
Univ South Florida
Saneron Ccel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Saneron Ccel Therapeutics Inc filed Critical Univ South Florida
Publication of BRPI0516992A publication Critical patent/BRPI0516992A/pt
Publication of BRPI0516992A8 publication Critical patent/BRPI0516992A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODO DE POTENCIALIZAR MODULAçAO IMUNE E INFLAMATóRIA PARA CéLULA E TERAPIA DE DROGA. Um método para reparar dano a tecido de animal devido a uma reação de inflamação em um animal tendo as etapas de fornecer células sanguíneas de cordão umbilical (UCBCs) em uma forma farmaceuticamente aceitável; e administrar uma dose suficiente de UCBC em um tempo ótimo, desse modo reduzindo a lesão proveniente da reação inflamatória. Também é fornecido um método de tratar acidente cerebrovascular, inflamação aguda do sistema nervoso central, esclerose múltipla, isquemia do miocárdio, e sofrimento broncopulmonar neonatal. Para determinar o tempo ótimo de administração de UCBCs, é fornecido um kit que contém anticorpos para IL-8 e MCP-1.
BRPI0516992A 2004-10-22 2005-10-24 Método de potencializar modulação imune e inflamatória para célula e terapia de droga BRPI0516992A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62134104P 2004-10-22 2004-10-22
PCT/US2005/038565 WO2006047593A2 (en) 2004-10-22 2005-10-24 Method of potentiating inflammatory and immune modulation for cell and drug therapy

Publications (2)

Publication Number Publication Date
BRPI0516992A true BRPI0516992A (pt) 2008-09-30
BRPI0516992A8 BRPI0516992A8 (pt) 2018-04-03

Family

ID=36228421

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516992A BRPI0516992A8 (pt) 2004-10-22 2005-10-24 Método de potencializar modulação imune e inflamatória para célula e terapia de droga

Country Status (3)

Country Link
US (1) US20060159666A1 (pt)
BR (1) BRPI0516992A8 (pt)
WO (1) WO2006047593A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
WO2005059115A1 (en) * 2003-12-15 2005-06-30 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
RU2535966C2 (ru) * 2008-09-12 2014-12-20 Криопрашис Криобиоложия Лтда. Клеточная терапия ишемической ткани
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US10765706B2 (en) 2015-09-03 2020-09-08 University Of South Florida Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
US20210275583A1 (en) * 2017-01-12 2021-09-09 Duke University Compositions and methods for the treatment of demyelinating conditions
WO2018132728A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for the treatment of demyelinating conditions
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP1257826A2 (en) * 2000-02-10 2002-11-20 The Research Foundation Of State University Of New York A method for detecting bacterial exacerbations of chronic lung disease
AU2001243464B2 (en) * 2000-03-09 2006-04-13 Saneron Ccel Therapeutics, Inc. Human cord blood as a source of neural tissue for repair of the brain and spinal cord
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
US20040197310A1 (en) * 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
AU2004212009B2 (en) * 2003-02-13 2010-07-29 Celularity Inc. Use of umbilical cord blood to treat individuals having a disease, disorder or condition

Also Published As

Publication number Publication date
WO2006047593A2 (en) 2006-05-04
US20060159666A1 (en) 2006-07-20
BRPI0516992A8 (pt) 2018-04-03
WO2006047593A3 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
BRPI0516992A (pt) método de potencializar modulação imune e inflamatória para célula e terapia de droga
Kolb et al. Folate deficiency enhances the inflammatory response of macrophages
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
BR112013004685A2 (pt) composição e método para reparação e regeneração muscular
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
AR039985A1 (es) Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR0317898A (pt) Imunoterapia de malignidades de células b e doenças auto-imunes usando anticorpos não conjugados e conjugados, combinações de anticorpos e proteìnas de fusão
ES2572211T3 (es) Regeneración de músculo esquelético utilizando células madre mesenquimales
UA124239U (uk) Спосіб лікування раку молочної залози
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
NO20080244L (no) Doseringsstyring for prasugrel
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
CO6300936A2 (es) Procedimiento para revertir la remodelacion cardiaca electrofisiologica de un animal con cardiopatia usando beta-adrenoceptores
Pandey et al. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
MX2022009081A (es) Absorcion celular.
RU2353358C2 (ru) Производные прегабалина для лечения приливов
JP2010510495A5 (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/00 (2006.01), A61K 35/51 (2015.01), A61P 29

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL